血管生成抑制剂在去势抵抗性前列腺癌治疗中的新发现

Antiangiogenic drugs for castration-resistant prostate cancer: Recent findings

近年来,去势抵抗性前列腺癌的治疗方法已由传统的抗雄激素及化疗提升到新的雄激素受体信号抑制剂、新一代紫杉醇及免疫疗法阶段。卡巴他赛、恩杂鲁胺、阿比特龙,放射性同位素镭223和sipuleucel-T随机临床试验显示能延长去势抵抗性前列腺癌患者生存期。然而,最终出现肿瘤抵抗也是难免的,去势抵抗性前列腺癌仍是一种主要临床负担,迫切需求新的治疗方法进一步改善CRPC患者生存期及生活质量。新生血管在前列腺癌的形成和进程中发挥至关重要的作用。部分临床试验显示,对失去手术和内分泌治疗时机的去势抵抗性前列腺癌,抗新生血管形成的靶向治疗是一种有效的补充疗法。本文将综述血管生成抑制剂在去势抵抗性前列腺癌治疗中的新发现。

In the recent years,treatment options for castration-resistant prostate cancer have evolved from conventional antiandrogens and chemotherapy to novel androgen receptor signaling inhibitors,a new generation of taxanes,and immunotherapy. Randomized clinical trials have shown that docetaxel,cabazitaxel,enzalutamide,abiraterone acetate,radium-223,and sipuleucel-T can improve the overall survival of the patients with androgen-independent prostate cancer. However,drug resistance is inevitable and androgen-independent prostate cancer remains a major clinical burden,which urgently calls for novel therapeutic options for the improvement of the patients＇ survival and quality of life. Angiogenesis plays a central role in the formation and progression of prostate cancer,and the antiangiogenic targeted therapy is shown in many clinical trials to be an effective therapeutic supplement for advanced prostate cancer beyond surgery and endocrine treatment. This article presents an overview on the recent findings of antiangiogenic drugs for castrationresistant prostate cancer.